Dupont Capital Management’s Blueprint Medicines BPMC Stock Holding History

Dupont Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,839	Closed	-$518K	–	1706
2021 Q4	$518K	Sell	4,839 -8,155	-63%	-$853K	0.02%	761
2021 Q3	$1.34M	Buy	12,994 +158	+1%	+$14.7K	0.04%	450
2021 Q2	$1.13M	Sell	12,836 -1,693	-12%	-$155K	0.03%	534
2021 Q1	$1.41M	Sell	14,529 -396	-3%	-$39.5K	0.03%	474
2020 Q4	$1.67M	Buy	+14,925	New	+$1.57M	0.04%	387
2019 Q2	–	Sell	-5,725	Closed	-$458K	–	1207
2019 Q1	$458K	Hold	5,725	–	–	0.01%	786
2018 Q4	$309K	Hold	5,725	–	–	0.01%	923
2018 Q3	$447K	Sell	5,725 -6,560	-53%	-$456K	0.01%	739
2018 Q2	$780K	Hold	12,285	–	–	0.02%	608
2018 Q1	$1.13M	Buy	12,285 +3,955	+47%	+$341K	0.03%	488
2017 Q4	$628K	Hold	8,330	–	–	0.01%	609
2017 Q3	$580K	Hold	8,330	–	–	0.01%	640
2017 Q2	$422K	Buy	+8,330	New	+$354K	0.01%	717

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Dupont Capital Management's BPMC Position: Q1 2022 in Review

Dupont Capital Management sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 4,839 shares — an estimated $518K sold.

Dupont Capital Management first reported a position in BPMC in Q2 2017 and held it in 13 quarters. The position peaked at $1.67M in Q4 2020. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

Dupont Capital Management reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
Dupont Capital Management sold 4,839 Blueprint Medicines shares in Q1 2022, an estimated $518K.
Dupont Capital Management first reported a position in Blueprint Medicines in Q2 2017 and held it in 13 quarters.
Dupont Capital Management's Blueprint Medicines position peaked at $1.67M in Q4 2020.
248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Dupont Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.